These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 17290341)

  • 1. [Hormonal pharmacotherapy: balancing between politics and evidence-based medicine].
    van Panhuis PJ
    Tijdschr Psychiatr; 2007; 49(2):117-8. PubMed ID: 17290341
    [No Abstract]   [Full Text] [Related]  

  • 2. [Side effects of treatment with the long-acting gonadorelin agonist triptorelin in a case of paraphilia].
    Hoogeveen JH; van der Veer E
    Tijdschr Psychiatr; 2007; 49(2):111-5. PubMed ID: 17290340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged flare-up of testosterone after administration of a gonadotrophin agonist to a sex offender: an under-recognised risk?
    Huygh J; Verhaegen A; Goethals K; Cosyns P; De Block C; Van Gaal L
    Crim Behav Ment Health; 2015 Jul; 25(3):226-30. PubMed ID: 25851640
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of men with paraphilia.
    Bradford JM
    N Engl J Med; 1998 Feb; 338(7):464-5. PubMed ID: 9459652
    [No Abstract]   [Full Text] [Related]  

  • 5. Side effects of pharmacotherapy on bone with long-acting gonadorelin agonist triptorelin for paraphilia.
    Hoogeveen J; Van der Veer E
    J Sex Med; 2008 Mar; 5(3):626-30. PubMed ID: 17971105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Urolithiasis in the Long-Term GnRH Agonist Treatment of Patients with Paraphilia: 3 Case Studies].
    Mayrhofer G; Wegner D; Voß T
    Aktuelle Urol; 2016 Dec; 47(6):487-490. PubMed ID: 27701680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescription of testosterone-lowering medications for sex offender treatment in German forensic-psychiatric institutions.
    Turner D; Basdekis-Jozsa R; Briken P
    J Sex Med; 2013 Feb; 10(2):570-8. PubMed ID: 23088739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacotherapy of paraphilias with long-acting agonists of luteinizing hormone-releasing hormone: a systematic review.
    Briken P; Hill A; Berner W
    J Clin Psychiatry; 2003 Aug; 64(8):890-7. PubMed ID: 12927003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gonadotrophin-releasing hormone agonists induce osteoporosis.
    Maillefert JF; Sibilia J; Kuntz JL; Tavernier C
    Br J Rheumatol; 1994 Dec; 33(12):1199-200. PubMed ID: 8000764
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacologic treatment of paraphilias.
    Assumpção AA; Garcia FD; Garcia HD; Bradford JM; Thibaut F
    Psychiatr Clin North Am; 2014 Jun; 37(2):173-81. PubMed ID: 24877704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hair loss in children on long-acting gonadotropin-releasing hormone agonist triptorelin treatment.
    Kauschansky A; Lurie R; Ingber A
    Acta Derm Venereol; 1997 Jul; 77(4):333. PubMed ID: 9228240
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacotherapy of paraphilias with luteinizing hormone-releasing hormone agonists.
    Briken P
    Arch Gen Psychiatry; 2002 May; 59(5):469-70; author reply 470. PubMed ID: 11982456
    [No Abstract]   [Full Text] [Related]  

  • 13. New-onset psychosis following androgen deprivation therapy for prostate cancer.
    Bernad DM; Dal Pra A; Baule C; Frey BN; Faria S
    Can J Urol; 2013 Aug; 20(4):6868-70. PubMed ID: 23930615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3-month triptorelin in premenopausal patients with hormone receptor-positive early breast cancer: a commentary and a retrospective experience.
    Caruso M; Castiglione G; Aiello R; Alí M; Chiarenza M; Dimarco R; Fallica G; Di Leo MG; Sanó MV; Taibi E; Zacchia A; Miano E; Caruso F
    Future Oncol; 2015; 11(23):3109-12. PubMed ID: 26544787
    [No Abstract]   [Full Text] [Related]  

  • 15. Gonadotropin-releasing hormone agonists for the preservation of ovarian function during chemotherapy.
    Tomao F; Benedetti Panici P; Tomao S
    J Clin Oncol; 2012 Sep; 30(26):3310-1; author reply 3312-3. PubMed ID: 22649128
    [No Abstract]   [Full Text] [Related]  

  • 16. [Gonadotropin-releasing agonist in the therapy of patients with laparoscopically confirmed endometriosis].
    Pŭnevska M; Filipov E; Nalbanski A; Nalbanski B
    Akush Ginekol (Sofiia); 2004; 43 Suppl 4():58-60. PubMed ID: 15673017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gonadotropin-releasing hormone agonist for preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.
    Blumenfeld Z
    J Clin Oncol; 2012 Sep; 30(26):3310; author reply 3312-3. PubMed ID: 22649145
    [No Abstract]   [Full Text] [Related]  

  • 18. Potential late effect of gonadotropin-releasing hormone agonists in combination with chemotherapy for early breast cancer.
    Saloustros E; Stratakis CA
    J Clin Oncol; 2012 Sep; 30(26):3311-2. PubMed ID: 22649148
    [No Abstract]   [Full Text] [Related]  

  • 19. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
    Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O
    Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Issues to consider in the assessment and treatment of paraphilic patients.
    Saleh FM
    J Clin Psychiatry; 2005 Jun; 66(6):802-3; author reply 803. PubMed ID: 15960581
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.